Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROFIT: PULSAR and FMT for Reversing Resistance in Advanced HCC
NCT07463248Phase 2Recruiting
- Start
- Apr 2026
- Primary completion
- Jan 2028
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of Fecal Microbiota Transplantation Capsule in hepatocellular carcinoma (HCC). Started Apr 2026; status: recruiting.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07463248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07463248.